| Bioactivity | IRAK4-IN-18 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 15 nM. IRAK4-IN-18 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-18 can be used for researching arthritis disease[1]. |
| Invitro | IRAK4-IN-18 (compound 33) has inhibitory activity against LPS-induced IL23 in THP and DC with IC50s of 0.25 and 0.14 μM, respectively[1]. |
| In Vivo | IRAK4-IN-18 (5, 10 and 20 mg/kg; twice daily for 21 days) exhibits good efficacy in a mouse model for the inhibition of IL-6 production induced by IL-1β, and completely stops arthritis development in arthritis rats at 30 mg/kg[1].IRAK4-IN-18 (1 mg/kg for IV, 5 mg/kg for PO, single dosage) exhibits a favorable pharmacokinetics profile with a clearance of 53 mL/min/kg and oral bioavailability of 38%[1]. Animal Model: |
| Name | IRAK4-IN-18 |
| Formula | C24H25FN6O3 |
| Molar Mass | 464.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen Y, et al. Bicyclic pyrimidine compounds as potent IRAK4 inhibitors. Bioorg Med Chem Lett. 2022 Jul 18:128900. |